Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-64991524
- Development stage
- Phase 1
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JNJ-64991524 is an investigational small molecule drug developed by Janssen Research & Development, a subsidiary of Johnson & Johnson. The compound has been evaluated in phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers. As of the latest available information, the specific mechanism of action and therapeutic indication for JNJ-64991524 have not been disclosed publicly. No associated conditions or active indications are reported in public databases[1][2][3][4].
- Other names
- JNJ 64991524JNJ64991524JNJ-64991524
Beyond the preview
Go deeper on JNJ-64991524.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-64991524.